Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.46USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
104,244
52-wk High
$1.39
52-wk Low
$0.38

Latest Key Developments (Source: Significant Developments)

Auris Medical Reports Q3 Loss Per Share CHF 0.14
Tuesday, 28 Nov 2017 06:40am EST 

Nov 28 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE CHF 0.14.‍NET LOSS FOR Q3 OF 2017 WAS CHF 6.0 MILLION, OR CHF 0.14 PER SHARE​.EXPECTS THAT ITS OPERATING EXPENSES IN 2017 WILL BE LOWER THAN PREVIOUS GUIDANCE OF CHF 28 TO 32 MILLION​.‍EXPECTS THAT EXISTING CASH AND CASH EQUIVALENTS WILL ENABLE FUNDING OF OPERATIONS INTO Q2 OF 2018​.  Full Article

Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
Tuesday, 28 Nov 2017 06:40am EST 

Nov 28 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS.AURIS MEDICAL HOLDING AG SAYS HEALOS TRIAL DID NOT MEET PRIMARY EFFICACY ENDPOINT IN OVERALL STUDY POPULATION.AURIS MEDICAL SAYS IN HEALOS TRIAL, CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENT IN SUBPOPULATION OF PATIENTS WITH PROFOUND ACUTE HEARING LOSS.AURIS MEDICAL SAYS BASED ON FINDINGS FROM HEALOS TRIAL, CONCLUDED THAT SIMILAR DESIGN OF ONGOING ASSENT TRIAL NO LONGER ADEQUATE FOR TESTING AM-111.AURIS MEDICAL HOLDING AG SAYS BASED ON FINDINGS FROM HEALOS TRIAL, ASSENT TRIAL WILL BE TERMINATED EARLY.  Full Article

Auris Medical Holding AG files for resale of up to 7.2 mln common shares
Thursday, 12 Oct 2017 04:37pm EDT 

Oct 12 (Reuters) - Auris Medical Holding Ag :Auris Medical Holding AG files for resale of up to 7.2 million common shares by selling shareholder, LPC Capital Fund Llc‍​ - SEC Filing.  Full Article

Auris Medical announces share purchase agreements with Lincoln Park Capital Fund
Wednesday, 11 Oct 2017 06:46am EDT 

Oct 11 (Reuters) - Auris Medical Holding Ag :Auris Medical announces share purchase agreements with Lincoln Park Capital Fund, Llc.Auris Medical Holding AG - ‍execution of two share purchase agreements for up to $15.0 million with Lincoln Park Capital Fund, Llc​.Auris Medical Holding - ‍pursuant to agreement dated Oct 10 Auris Medical may require LPC, to subscribe for up to $13.5 million worth of its common shares​.Auris Medical Holding- on Oct 10, Auris entered into purchase agreement with LPC as per which LPC subscribed for $1.5 million worth of Auris's shares​.  Full Article

Auris Medical announces transfer to Nasdaq capital market
Thursday, 28 Sep 2017 08:30am EDT 

Sept 28 (Reuters) - Auris Medical Holding Ag :Auris Medical announces transfer to Nasdaq capital market.Auris Medical Holding AG - co's shares will continue to trade uninterrupted under symbol "EARS."​.Auris Medical-approval of co's request to Nasdaq Stock Market Llc to transfer listing of common shares To Nasdaq Capital Market from Nasdaq Global Market.  Full Article

Auris Medical completes patient recruitment for phase 3 trial of Keyzilen in acute and post-acute tinnitus
Friday, 22 Sep 2017 08:00am EDT 

Sept 22 (Reuters) - Auris Medical Holding Ag :Auris Medical completes patient recruitment for phase 3 TACTT3 trial of Keyzilen in acute and post-acute tinnitus.Auris Medical Holding Ag - ‍top-line results from TACTT3 trial are expected in Q1 of 2018​.  Full Article

Auris Medical posts Q2 loss per share CHF 0.12
Thursday, 10 Aug 2017 06:31am EDT 

Aug 10 (Reuters) - Auris Medical Holding AG :Auris Medical provides business update and reports second quarter 2017 financial results.Q2 loss per share CHF 0.12.Auris Medical Holding AG - ‍continues to expect that its operating expenses in 2017 will be in range of CHF 28 to 32 million​.Auris Medical Holding AG - ‍continues to expect that existing cash and cash equivalents will enable funding of operations into q1 of 2018​.  Full Article

Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafness
Wednesday, 5 Jul 2017 08:01am EDT 

July 5 (Reuters) - Auris Medical Holding AG ::Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafness.Auris Medical Holding AG - ‍top-line results from healos trial are expected in fall of 2017.​.Says ‍auris Medical expects to announce top-line results from assent trial in second half of 2018​.Auris Medical Holding AG - ‍primary efficacy endpoint for trial is improvement of pure tone hearing thresholds from baseline to day 28​.  Full Article

Auris Medical reports Q1 loss per share chf 0.22
Thursday, 11 May 2017 06:16am EDT 

May 11 (Reuters) - Auris Medical Holding Ag : :Auris Medical provides business update and reports first quarter 2017 financial results.Q1 loss per share chf 0.22.Auris Medical Holding AG - net loss for q1 of 2017 was chf 8.4 million, or chf 0.22 per share.Auris Medical Holding AG - continues to expect that its operating expenses in 2017 will be in range of chf 28 to 32 million.Auris Medical Holding AG - continues to expect existing cash and cash equivalents will enable funding of operations into q1 of 2018.  Full Article

Auris Medical reports key results from Keyzilen Ampact2 open-label extension study
Monday, 24 Apr 2017 08:01am EDT 

April 24 (Reuters) - Auris Medical Holding Ag :Auris medical reports key results from Keyzilen Ampact2 open-label extension study.Trial outcomes show positive safety profile of Keyzilen for chronic intermittent use.Exploratory efficacy results support therapeutic concept of early tinnitus treatment.Says trial outcomes show positive safety profile of Keyzilen for chronic intermittent use.Says auris medical expects to announce results from ampact1, open-label extension study related to TACTT2, later this quarter.TACTT3 extended to recruit additional 60 patients in each of stratum A and B, enrollment ongoing; top-line results expected in early 2018.As recruitment for Ampact2 has completed, open-label extension is not offered to patients currently enrolling in extended TACTT3 trial.  Full Article

UPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped

* Shares plummet >50 pct to $0.38 (Adds background, details on Auris' pipeline; updates shares)